Loading...
•
Jun 30, 2022
Vanda Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022.
Key Takeaways
Vanda Pharmaceuticals reported Q2 2022 total revenues of $64.4 million, a 5% decrease compared to Q2 2021. Net income was $2.6 million, compared to $9.7 million in the same period last year.
Total revenues were $64.4 million in the second quarter of 2022.
HETLIOZ® net product sales were $41.2 million in the second quarter of 2022, a 7% decrease compared to $44.5 million in the second quarter of 2021.
Fanapt® net product sales were $23.2 million in the second quarter of 2022, a 1% decrease compared to $23.4 million in the second quarter of 2021.
Net income was $2.6 million in the second quarter of 2022 compared to $9.7 million in the second quarter of 2021.
Revenue by Segment
Forward Guidance
Vanda expects total revenues between $240 to $280 million, HETLIOZ® net product sales between $150 to $180 million, Fanapt® net product sales between $90 to $100 million and year-end cash greater than $440 million for full year 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...